Establishment and characterization of two uveal melanoma cell lines derived from tumors with loss of one chromosome 3

Establishment and characterization of two uveal melanoma cell lines derived from tumors with loss of one chromosome 3
复制标题

DOI:
10.1016/j.exer.2006.04.004
复制
发表时间:
2006-10-01
影响因子:
3.4
通讯作者:
Anastassiou, Gerasimos
Anastassiou, Gerasimos
中科院分区:
医学3区
文献类型:
--
作者:
Nareyeck, Gordon;Zeschnigk, Michael;Anastassiou, Gerasimos

文献摘要

被引文献

相似文献

葡萄膜黑色素瘤是最常见的眼内恶性肿瘤。大约50%的UM患者死于转移,其主要由具有整个3号染色体(3号单体)丢失的原发性肿瘤引起。为了鉴定具有单体3的细胞系,其可以作为具有高转移潜力的UM的模型系统,我们通过微卫星分析(Me 1202、Me 1285、Me 1290、92-1、OMM-1、OCM-1、OCM-3、OCM-8)和细胞遗传学分析(Me 1202、Me 1285、OCM-8)确定先前建立的和常用的UM细胞系的染色体3状态。我们发现这些细胞系都没有单体3。因此,我们建立并表征了两种新的细胞系,UPMM-1和UPMM-2,它们都是从具有单体3的原发性葡萄膜黑色素瘤组织样品中开发的。细胞系UPMM-1保留了原发性肿瘤的3号染色体状态。在UPMM-2中,3号染色体经历了重复(等二体性),并存在于亚四倍体核型的背景上。我们的数据表明,UPMM-1可以作为一个模型系统,以研究葡萄膜黑色素瘤的转移潜力与单体3的机制。(c)2006爱思唯尔有限公司保留所有权利。
Uveal melanoma (UM) is the most common intraocular malignancy. Approximately 50% of UM patients die of metastases, which mainly arise from primary tumors with loss of an entire chromosome 3 (monosomy 3). To identify cell lines with monosomy 3 that may serve as,a model system for UM with high metastatic potential, we determined the chromosome 3 status of previously established and frequently used UM cell lines by microsatellite analysis (Me1202, Me1285, Me1290, 92-1, OMM-1, OCM-1, OCM-3, OCM-8) and cytogenetic analysis (Me1202, Me1285, OCM-8). We found that none of these cell lines has monosomy 3. Therefore we established and characterized two novel cell lines, UPMM-1 and UPMM-2 that are both developed from primary uveal melanoma tissue samples with monosomy 3. The cell line UPMM-1 has retained the chromosome 3 status of the primary tumor. In UPMM-2 chromosome 3 has undergone duplication (isodisomy) and is present on the background of a hypotetraploid karyotype. Our data suggest that, UPMM-1 may serve as a model system to study the mechanisms underlying the metastatic potential of uveal melanomas with monosomy 3. (c) 2006 Elsevier Ltd. All rights reserved.